Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Group 1: Company Overview - Haiprui's main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin raw materials [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company has a total market capitalization of 17.123 billion yuan, with a trading volume of 33.7636 million yuan and a turnover rate of 0.23% on December 15 [1]. Group 2: Financial Performance - The overseas revenue contribution for Haiprui is 93.04%, benefiting from the depreciation of the Renminbi [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - Haiprui operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including biopharmaceuticals, raw materials, vaccines, and innovative drugs [7]. - The stock has shown a net inflow of 605,300 yuan from major investors, indicating a lack of clear trend in major holdings, with the stock's average trading cost at 11.59 yuan [5][6].

Core Insights - A new company, Haipuri (Shanghai) Semiconductor Materials Co., Ltd., has been established with a registered capital of 1 million RMB [1] Group 1: Company Overview - The legal representative of the company is Zhang Jie [1] - The business scope includes general projects such as technology services, development, consulting, and transfer [1] - The company is also involved in import and export activities, including goods and technology [1] Group 2: Specific Business Activities - The company will engage in the sale of electronic measuring instruments and semiconductor device specialized equipment [1] - Additional activities include sales of rubber products, hardware products, plastic products, and electronic specialized equipment [1] - The company will also provide services in engineering and technology research, development, and maintenance of electronic and mechanical equipment [1]

Core Viewpoint - The financial performance of Haiprui (09989) for Q3 2025 shows a slight improvement in revenue but a significant decline in net profit, indicating mixed market sentiment and technical challenges for the stock [1][2]. Financial Performance - For the first three quarters of this year, Haiprui achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09% [1]. - The net profit attributable to shareholders was 554 million yuan, reflecting a year-on-year decline of 29.04% [1]. Stock Market Reaction - Following the Q3 report, Haiprui's stock experienced a brief rally, with a five-day consecutive increase from November 7 to November 13, but failed to sustain momentum due to low trading volume [1][2]. - The stock price entered a downward trend after this brief rally, declining over six trading days and fluctuating between the lower and middle Bollinger Bands [2]. Trading Activity - Recent trading data indicates that major sell-side positions were held by Citibank, BNP Paribas, Morgan Stanley, Merrill Lynch, and HSBC, while the main buyers were China Investment and China Chuangying [6][7]. - The proportion of shares held by Hong Kong Stock Connect investors in Haiprui has increased to 43.14% [6]. Industry Context - The heparin industry is cyclical and closely tied to the pig farming cycle, with China being the largest supplier of heparin raw materials globally [8]. - Historical data shows that heparin prices are highly sensitive to supply and demand changes, with significant price fluctuations observed in recent years due to various market conditions [8][9]. Market Outlook - Despite the current "strong supply, weak demand" situation in the pig market, there are optimistic expectations for a recovery in pig prices by mid-2024, which could positively impact the heparin market [9]. - The stock price of Haiprui in A-shares has increased by 81.63% from its low point, while the Hong Kong stock price remains at a significant discount compared to A-shares, suggesting potential investment opportunities [9].

Financial Performance - In the first three quarters of 2023, the company reported revenue of 4.194 billion yuan, a year-on-year increase of 3.09% [1] - The net profit attributable to shareholders was 554 million yuan, a year-on-year decrease of 29.04% [1] Stock Market Reaction - Following the earnings report, the company's stock experienced a brief rally, achieving five consecutive days of gains from November 7 to November 13 [2] - However, this upward momentum did not lead to sustained price increases, and the stock entered a downward trend, declining over six trading days [2][4] Technical Analysis - The stock has been in a downward trend since late July, with a peak of 7.26 HKD on July 21, followed by a series of declines [3] - After the Q3 report, the stock saw a temporary rise but failed to maintain volume support, leading to a "false breakout" scenario [4] Market Sentiment and Trading Activity - During a period of low trading activity, there were signs of bottom-fishing by investors, particularly through the Hong Kong Stock Connect [6] - Recent trading data indicated that the proportion of shares held by Hong Kong Stock Connect investors reached 43.14% [9] Industry Context - The heparin industry is cyclical and closely tied to the pig farming cycle, with China being the largest supplier of heparin raw materials globally [11] - Historical data shows that heparin prices are highly sensitive to supply and demand changes, with significant price fluctuations observed in recent years [12] Future Outlook - The market anticipates a potential recovery in pig prices by mid-2024, which could positively impact the heparin market [12] - The company's A-share price has increased by 81.63% from its low point, while the Hong Kong stock remains undervalued compared to its A-share counterpart [13]

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has announced the extension of the duration of its second and third employee stock ownership plans during the 19th meeting of the sixth board of directors held on December 5, 2025 [2][3][6]. Group 1: Board Meeting Details - The 19th meeting of the sixth board of directors was held on December 5, 2025, with all 7 directors participating in the voting [2]. - The meeting was presided over by Chairman Li Li and complied with relevant laws and regulations [2]. Group 2: Resolutions Passed - The board approved the extension of the second employee stock ownership plan's duration, with a unanimous vote of 7 in favor [3]. - The board also approved the extension of the third employee stock ownership plan's duration, again with a unanimous vote of 7 in favor [4]. Group 3: Employee Stock Ownership Plans Overview - The second employee stock ownership plan was initially approved on December 12, 2016, with a duration of 36 months, set to expire on December 11, 2019 [6]. - The plan has been extended multiple times, with the latest extension pushing the expiration date to December 11, 2024, and currently has 15,118,035 shares remaining unsold, representing 73.32% of the total purchased shares [8]. - The third employee stock ownership plan was approved on December 28, 2018, with an initial duration of 24 months, set to expire on December 27, 2020 [9]. - Similar to the second plan, the third plan has also been extended multiple times, with the latest extension moving the expiration date to December 27, 2025, and currently holds all purchased shares unsold [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 海外監管公告 本公告乃深圳市海普瑞藥業集團股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第13.10B條而作出。 兹載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 於本公告日期，本公司執行董事為李鋰先生、李坦女士、單宇先生及張平先生； 本公司獨立非執行董事為呂川博士、黃鵬先生及易銘先生。 承董事會命 深圳市海普瑞藥業集團股份有限公司 李鋰 董事長 中國深圳，2025年12月5日 证券代码：002399 证券简称：海普瑞 公告编号：2025-038 深圳市海普瑞药业集团股份有限公司 关于延长员工持股计划存续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃深圳市海普瑞藥業集團股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第13.10B條而作出。 兹載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 深圳市海普瑞藥業集團股份有限公司 李鋰 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 海外監管公告 董事長 中國深圳，2025年12月5日 於本公告日期，本公司執行董事為李鋰先生、李坦女士、單宇先生及張平先生； 本公司獨立非執行董事為呂川博士、黃鵬先生及易銘先生。 证券代码：002399 证券简称：海普瑞 公告编号：2025-037 深圳市海普瑞药业集团股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 ...

证券代码：002399 证券简称：海普瑞 公告编号：2025-038 深圳市海普瑞药业集团股份有限公司 关于延长员工持股计划存续期的公告 2020年12月4日，公司召开的第五届董事会第五次会议审议通过了《关于延 长公司第二期员工持股计划存续期的议案》，同意将公司第二期员工持股计划存 续期延长12个月至2021年12月11日止。 2021年12月10日，公司召开的第五届董事会第十五次会议审议通过了《关于 延长第二期员工持股计划存续期的议案》，同意将公司第二期员工持股计划存续 期延长12个月至2022年12月11日止。 2022年12月9日，公司召开的第五届董事会第二十四次会议审议通过了《关 于延长第二期员工持股计划存续期的议案》，同意将公司第二期员工持股计划存 续期延长12个月至2023年12月11日止。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）于2025年12月5 日召开的第六届董事会第十九次会议审议通过了《关于延长第二期员工持股计划 存续期的议案》及《关于延长第三期员工持股计划存续期的议案》，同意将 ...

证券代码：002399 证券简称：海普瑞 公告编号：2025-037 深圳市海普瑞药业集团股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 十九次会议（以下简称"会议"）通知及议案于2025年12月3日以电子邮件的形 式发出，会议于2025年12月5日下午14:00在深圳市南山区松坪山朗山路21号会议 室以现场与通讯相结合的方式召开。本次会议应参与表决董事7人，实际参与表 决董事7人，其中张平先生、黄鹏先生以通讯方式参与表决。公司监事及高级管 理人员列席会议，会议由公司董事长李锂先生主持。本次会议的通知、召开以及 参与表决董事人数均符合相关法律法规及《公司章程》的有关规定。 2、《关于延长第三期员工持股计划存续期的议案》 表决结果：7票同意、0票弃权、0票反对。 具体内容详见公司同日披露于《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网www.cninfo.com.cn的《关于延长员工持股计划存续 期的公告 ...

截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | ...